The global healthcare contract development and manufacturing organization market size was valued at USD 249.9 billion in 2023 and is projected to grow at a CAGR of 9.68% from 2024 to 2030. An increase in the uptake of outsourcing services by pharmaceutical & medical devices companies and growth in R&D investments are expected to drive the market.
Read More »July 9, 2024
Our healthcare portfolio has been developing since our inception in 2014, wherein we have tracked numerous sub-domains and their R&D activities. We have actively been tracking the CDMOs space and have seen the evolution of these players from just a handful to now over 100 companies.
Read More »August 13, 2024
The global biopharmaceutical CMO and CRO market size was valued at USD 36.21 billion in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2030. There was unprecedented growth in 2020 due to the COVID-19 pandemic. The rising investments in the biopharmaceutical industry by the prominent participants to enhance their productivity and efficiency have driven the bio manufacturers to increase their focus on outsourcing activities.
Read More »January 6, 2022
The global large molecule drug substance CDMO market size was valued at USD 11.5 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 9.3% from 2023 to 2030. Increasing large molecule drug approvals, primarily with the FDA, rising incidence of infectious diseases, high demand for novel therapeutics, and higher capital investments by pharma and biotech firms in advanced technologies for establishing partnerships with CDMOs are the key factors driving the market.
Read More »November 23, 2022
The U.S. biopharmaceutical CMO & CRO market size was valued at USD 10.1 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.1% from 2023 to 2030. Increasing adoption and investment in advanced research and manufacturing technologies by Contract Manufacturing Organizations (CMOs) & Contract Research Organizations (CROs) based in the U.S. is propelling the growth of the biopharmaceutical CMO & CRO market in the country.
Read More »February 28, 2023
The global investigational new drug CDMO market size was valued at USD 4.88 billion in 2023 and is expected to grow at a CAGR of 6.9% from 2024 to 2030. Pharmaceutical companies' significant use of outsourcing services, increased spending on research and development, and stricter laws governing clinical study conduct can all be credited with the market's growth.
Read More »August 7, 2024
Our healthcare portfolio has been developing since our inception in 2014, wherein we have tracked numerous sub-domains and their R&D activities. We have actively been tracking the CROs space and have seen the evolution of these players from just a handful to now over 100 companies.
Read More »April 12, 2023
The growing number of clinical trials across the globe in past few years has significantly increased the overall clinical trial costs. High clinical cost of clinical trial is owing to complexity of novel therapies such as personalized medicine and cell & gene therapy, and stringent regulatory requirements.
Read More »August 16, 2024
The North America topical drugs CDMO market size was estimated at USD 13.03 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2030. Rising healthcare outsourcing, improved patient care, R&D investments due to rising prevalence of various skin diseases, and expiration of existing patents are driving the topical drugs CDMO market in North America.
Read More »January 31, 2024
The global topical drugs CDMO market size was estimated at USD 41.54 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2030. Growth in the aesthetic and cosmetic industry has significantly driven demand for topical drugs, thereby simultaneously boosting demand for contract development and manufacturing services.
Read More »November 2, 2023